P2Y12 receptor inhibitors: Integrating ticagrelor into the management of acute coronary syndrome

Annals of Pharmacotherapy

Volumn 45, Issue 9, 2011, Pages 1151-1156

  Crouch, Michael A ^a   Colucci, Vince J ^b   Howard, Patricia A ^c   Spinler, Sarah A ^d  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Acute coronary syndromes; Antiplatelet; Thienopyridines; Ticagrelor

Indexed keywords

CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; ADENOSINE; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ALGORITHM; BLEEDING; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DYSPNEA; HUMAN; NOTE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT PLANNING; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; PATHOPHYSIOLOGY;

ACUTE CORONARY SYNDROME; ADENOSINE; ALGORITHMS; DYSPNEA; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12;

EID: 80052508855     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q141     Document Type: Note

References (35)

1. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline). J Am Coll Cardiol 2011;57:1920-59. DOI 10.1016/j.jacc.2011.02.009
2. 2009 Focused update: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and ACC/AHA/SCAI guidelines on percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009;120:2271-306. DOI 10.1161/CIRCULATIONAHA.109.192663
3. Product information. Plavix (clopidogrel). Bridgewater, NJ: Bristol-Meyer Squibb/Sanofi Pharmaceuticals, February 2011.
4. Product information. Effient (prasugrel). Indianapolis, IN: Eli Lilly and Company, December 2010.
5. Product information. Brilinta (ticagrelor). Wilmington, DE: AstraZeneca, July 2011.
6. Mehta RH, Chen AY, Pollack CV, et al. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2006; 98:624-7. DOI 10.1016/j.amjcard.2006.03.040
7. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised platelet inhibition and patient outcomes (PLATO) trial. BMJ 2011;342:d3527. DOI 10.1136/bmj.d3527
8. Bonello L, Tantry U, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33. DOI 10.1016/j.jacc.2010.04.047
9. Nguyen TA, Dioidate JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005;45:1157-64. DOI 10.1016/j.jacc.2005.01.034
10. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial. N Engl J Med 2001;345:494-502. DOI 10.1056/NEJMoa010746
11. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33. DOI 10.1016/S0140-6736(01)05701- 4
12. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a ran-domized controlled trial. JAMA 2002;288:2411-20. DOI 10.1001/jama.288.19.2411
13. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89. DOI 10.1056/NEJ- Moa050522
14. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pre-treatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005;294:1224-32. DOI 10.1001/jama.294.10.1224
15. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol 2007;49:1505-16. DOI 10.1016/j.jacc.2006.11.044
16. Scott DM, Norwood RM, Parra D. P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. Ann Pharmacother 2009;43:64-76. DOI 10.1345/aph.1G726
17. Brandt, JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-66. DOI 10.1016/j.ahj.2006.10.010
18. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-32. DOI 10.1161/CIRCULATIONAHA.107.740324
19. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness (editorial). N Engl J Med 2009;360:411-3. DOI 10.1056/NEJMe0810513
20. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50:126-42. DOI 10.1177/0091270009343005
21. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357: 2001-15. DOI 0.1056/NEJMoa0706482
22. Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strategy to medically manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16-22.e1.DOI 10.1016/j.ahj.2010.04.022
23. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009;120:2577-85. DOI 10.1161/CIRCULATIONAHA.109.912550
24. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. DOI 10.1056/NEJMoa0904327
25. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery by-pass surgery results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011;57:672-84. DOI 10.1016/j.jacc.2010.10.029
26. NDA 22-433 Brilinta (ticagrelor) efficacy review: Cardio-Renal Advisory Committee Meeting, July 28, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Cardiovascu-larandRenalDrugsAdvisoryCommittee/UCM221383.pdf (accessed 2011 May 20).
27. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J 2009;157:599-605. DOI 10.1016/j.ahj.2009.01.003
28. Briefing information for the July 28, 2010, meeting of the Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm220190.htm (accessed 2011 Mar9).
29. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic sub-study of the PLATO trial. Lancet 2010;376:1320-8. DOI 10.1016/S0140-6736(10)61274-3
30. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010;3:556-66. DOI 10.1161/CIRCGENETICS.110.958561
31. Serebruany VL. Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? Am Heart J 2011;161:1-4. DOI 10.1016/j.ahj.2010.09.017
32. Scirica BM, Cannon CP, Emanuelsson H, et al. Incidence of brad-yarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol 2011;57: 1908-16. DOI 10.1016/j.jacc.2010.11.056
33. Janzon M, Lundborg E, Henriksson M, et al. Health economics in the PLATelet inhibition and Patient Outcomes (PLATO) randomized trial: report on within trial resource use patterns (abstract 17295). Circulation 2010;122:A17295.
34. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 2010;121:71-9.
35. FDA extends Plavix patent by 6 months to May 2012. http://www.ap.org (accessed 2011 May 20).